| Document |
Document Title |
|
WO/2024/111671A1 |
The present invention addresses the problem of providing a method for increasing affinity of a nucleic acid aptamer comprising 7-(2-thienyl)imidazo[4,5-b]pyridine (Ds base) for a target protein. Provided is a nucleic acid aptamer compr...
|
|
WO/2024/110505A1 |
The present invention relates to compositions and methods for treating tear film deficiencies in the eye by applying to the eye or the surrounding area a composition comprising hyaluronic acid.
|
|
WO/2024/064851A3 |
The disclosure relates to compositions and methods comprising recombinant AAV vectors comprising polynucleotide sequences encoding superoxide dismutase (SOD) proteins. Also included are methods of treating or preventing acute, progressiv...
|
|
WO/2023/205752A3 |
The present disclosure relates to ephrin ligand mimetic peptides and methods of treating neurodegenerative diseases, using the mimetic peptides.
|
|
WO/2024/110625A1 |
The present invention relates to compositions for use in methods of preventing or treating retinal diseases or disorders of an animal or a human, wherein said compositions comprise complexes comprising (a) a CRALBP protein, and (b) a cog...
|
|
WO/2024/109671A1 |
Disclosed are Cas9 protein, variants or homologues thereof-specific PROTAC degrader(s) of Formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, or a polymorph thereof, composition comprising the same, and uses thereof. The sai...
|
|
WO/2024/109905A1 |
The present invention belongs to the field of pharmaceutical formulations, and provides an ophthalmic formulation comprising a pyridine phenyl compound, a preparation method therefor, and use thereof. The ophthalmic formulation comprises...
|
|
WO/2024/108811A1 |
An amino-acid-modified compound containing a pillararene structural part, a linking group with a divalent triazole ring and an amino-acid-modified group, and a method for preparing the compound and the use thereof. The amino-acid-modifie...
|
|
WO/2024/109739A1 |
A novel pharmacologic treatment of refractive disorders including myopia and hyperopia is provided. The method of treating refractive disorders including myopia and hyperopia is mainly through targeting the Hippo biological pathway using...
|
|
WO/2024/111623A1 |
In one embodiment, the present disclosure provides an antisense oligonucleotide capable of restoring pseudo-exon type aberrant splicing. In one embodiment, provided is an antisense oligonucleotide for restoring pseudo-exon type aberrant ...
|
|
WO/2024/110770A1 |
Retinal pigment epithelium (RPE) structure and function are essential to normal vision, and alterations in the RPE can impair function and lead to retinopathy. Gene therapy is currently investigated for the treatment of retinal pigment e...
|
|
WO/2024/112957A1 |
The disclosure relates to compositions and methods that modify target nucleic acids, as well as methods of detecting nucleic acids. Various compositions are described herein, including compositions comprising endonucleases, endonuclease ...
|
|
WO/2024/104292A1 |
The present disclosure relates to crystalline forms of (S) -4- (2, 2-difluoro-7- ( (5-methoxy-7-methyl-1H-indol-4-yl) methyl) -7-azaspiro [3.5] nonan-6-yl) benzoic acid and pharmaceutical compositions and uses of same.
|
|
WO/2024/105197A1 |
The present invention relates to novel pharmaceutical compounds comprising one or more binding molecules (e.g., target protein binders, T) capable of binding to target proteins expressed on tumor cells or on cells present in the tumor mi...
|
|
WO/2024/104475A1 |
Disclosed in the present invention are cyclic compounds used as multi-target kinase inhibitors and a preparation method therefor. The multi-target kinase inhibitors of the present invention are represented by general formula I, wherein R...
|
|
WO/2024/108090A1 |
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including peripheral and/or systemic inflammator...
|
|
WO/2024/107012A1 |
The present invention relates to a novel microorganism, a lysate and culture medium thereof, and an extract of the culture medium, and to antiallergic uses thereof. A novel strain, and a lysate or culture medium derived therefrom, an ext...
|
|
WO/2024/104415A1 |
Provided is a use of a class of bisbenzylisoquinoline compounds as novel ferroptosis inhibitors, which inhibit ferroptosis by preventing the accumulation of lipid peroxides in living cells. Also provided is a use of the bisbenzylisoquino...
|
|
WO/2024/105689A1 |
The present invention relates to a novel pharmaceutical composition suitable for ophthalmic use comprising antibiotic such as plazomicin or its pharmaceutically acceptable salts and a process to prepare the same for use in the treatment ...
|
|
WO/2024/103142A1 |
Disclosed are peptides having specific affinity to exfoliation syndrome (XFS) deposits in a mammalian eye, and magnetic particle-peptide conjugates. Also disclosed are methods and uses of such magnetic particle-peptide conjugates to disp...
|
|
WO/2024/105016A1 |
The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n and R1 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are us...
|
|
WO/2024/105018A1 |
The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and whic...
|
|
WO/2024/105703A1 |
The present invention discloses an ophthalmic formulation/composition comprising cinnamic acids or their derivatives, catechins or its derivatives, either alone or in combination thereof together with acceptable excipients for treating/c...
|
|
WO/2024/106446A1 |
The present invention provides a composition for relieving or preventing the symptoms of allergic rhinitis or allergic conjunctivitis, etc., the composition containing dihomo-γ-linolenic acid (DGLA) as an active ingredient.
|
|
WO/2024/107398A1 |
A dietary supplement includes a xanthophyll carotenoid including lutein, zeaxanthin, and meso-zeaxanthin. The dietary supplement may include, for example, greater than or equal to about 0.27 weight percent to less than or equal to about ...
|
|
WO/2024/105673A1 |
The present invention is directed to, inter alia, a method for treating retinal disease using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the native splicing of exon 6 of a mutant nuclear receptor subf...
|
|
WO/2024/105417A1 |
A compound of Formula (I), or a composition thereof, for use in a method of prevention and/or treatment of a biofilm-related condition. A bio-active agent for use in a method of prevention and/or treatment of a biofilm-related condition,...
|
|
WO/2024/108095A1 |
Disclosed herein are ophthalmic compositions, such as nonaqueous liquid ophthalmic compositions, comprising at least one antibiotic, such as doxycycline, and at least one semifluorinated alkane, such as 1-perfluorohexyloctane (F6H8), as ...
|
|
WO/2024/105021A1 |
The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R3 and R are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which...
|
|
WO/2024/101918A1 |
The present invention relates to a lipo-hydroxamic acid derivative and a pharmaceutical use thereof, the derivative being usefully employable as a composition for prevention, treatment, or reduction of eye disease by having been confirme...
|
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/098127A1 |
The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous sol...
|
|
WO/2024/100628A1 |
The present disclosure describes formulations and methods for hydrating dry eyes. The formulations comprise at least one natural humectant, at least one amino acid, and at least one vitamin, wherein the formulation is preservative free, ...
|
|
WO/2024/099458A1 |
Disclosed in the present invention are a piperidine-substituted benzoic acid compound, and a pharmaceutical composition and the use thereof. The piperidine-substituted benzoic acid compound of the present invention is a compound as shown...
|
|
WO/2024/101859A1 |
The present invention relates to a sustained-release injectable preparation comprising dexamethasone acetate and a preparation method therefor.
|
|
WO/2024/101915A1 |
The present invention relates to a peptide nucleic acid complex having enhanced stability and improved inhibitory effects on a target gene, wherein the terminals of a bioactive peptide nucleic acid and a carrier peptide nucleic acid are ...
|
|
WO/2024/103000A1 |
Compositions, methods, and kits are provided for diagnosing and treating vestibular schwannoma. In particular, biomarkers associated with tumor growth and hearing loss have been identified that may be useful for diagnosing vestibular sch...
|
|
WO/2024/102798A1 |
Lipid nanoparticles that can be used as active molecule carriers for ophthalmic, dermatological, and/or cosmetic applications. The nanoparticles have an average particle size of less than 80 nm and a permeation enhancer that provides hig...
|
|
WO/2024/102346A1 |
This disclosure relates to methods of treating, e.g., eye pain and eye disorders, using dual N-type and L-type calcium channel blockers selective for the N-type calcium channel (e.g., cilnidipine).
|
|
WO/2024/102328A1 |
Methods are provided to prevent and to treat diabetic retinopathy by using Calcium channel blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, angiotensin receptor blockers (ARB), or vasodilators, and more particularly, to a method...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/101434A1 |
This physiologically-active peptide derivative for the treatment of eye diseases comprises a physiologically-active peptide sequence and a functional sequence comprising a membrane permeation-promoting sequence and an endosomal escape-pr...
|
|
WO/2024/102746A1 |
Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.
|
|
WO/2024/099478A1 |
A selective inhibitor of PI3Kδ, and a free base, isomer, solvate, pharmaceutically acceptable salt and other structural forms thereof. The compounds have significant antagonistic activity on PI3Kδ, and a pharmacokinetic study shows tha...
|
|
WO/2024/097900A1 |
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-2325 and compositions, methods, and uses thereof.
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/095026A1 |
In the present invention azidation is used to render a molecule photoactivable and to influence its binding to its cognate specific binding partner in the eye. Thus, the invention relates to a compound for use in a method of treating a s...
|
|
WO/2024/094759A1 |
There is provided herein a composition comprising liposomes, which comprise a lipid component and a phospholipid component, which compositions are useful in the treatment of ocular surface disorders.
|
|
WO/2024/096629A1 |
The present invention provides an eye drop composition for treating, preventing, or ameliorating dry eye syndrome or a dry eye-related disease, the eye drop composition comprising a compound represented by chemical formula 1 at a concent...
|
|
WO/2024/097439A1 |
A method of treating X-linked juvenile retinoschisis (XLRS) in a human subject includes subretinally delivering to the human subject a therapeutically effective amount of an rAAV vector. The rAAV vector includes a nucleic acid sequence c...
|
